Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms
Sa A. Wang, Robert P. Hasserjian, Patricia S. Fox, et al.
Blood (2014) Vol. 123, Iss. 17, pp. 2645-2651
Open Access | Times Cited: 201

Showing 1-25 of 201 citing articles:

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber, Attilio Orazi, Robert P. Hasserjian, et al.
Blood (2016) Vol. 127, Iss. 20, pp. 2391-2405
Open Access | Times Cited: 9112
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
David P. Steensma, Rafael Bejar, Siddhartha Jaiswal, et al.
Blood (2015) Vol. 126, Iss. 1, pp. 9-16
Open Access | Times Cited: 1720
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
Daniel A. Arber, Attilio Orazi, Robert P. Hasserjian, et al.
Blood (2022) Vol. 140, Iss. 11, pp. 1200-1228
Open Access | Times Cited: 1676
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
William J. Gradishar, Benjamin O. Anderson, Ronald Balassanian, et al.
Journal of the National Comprehensive Cancer Network (2018) Vol. 16, Iss. 3, pp. 310-320
Open Access | Times Cited: 1597
Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
Peter L. Greenberg, Richard M. Stone, Aref Al‐Kali, et al.
Journal of the National Comprehensive Cancer Network (2016) Vol. 15, Iss. 1, pp. 60-87
Open Access | Times Cited: 282
Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation
Kate J. Newberry, Keyur P. Patel, Lucia Masárová, et al.
Blood (2017) Vol. 130, Iss. 9, pp. 1125-1131
Open Access | Times Cited: 200
Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms
Laura Palomo, Manja Meggendorfer, Stephan Hütter, et al.
Blood (2020) Vol. 136, Iss. 16, pp. 1851-1862
Open Access | Times Cited: 151
Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib
Keyur P. Patel, Kate J. Newberry, Rajyalakshmi Luthra, et al.
Blood (2015) Vol. 126, Iss. 6, pp. 790-797
Open Access | Times Cited: 175
An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults
Michael R. Savona, Luca Malcovati, Rami S. Komrokji, et al.
Blood (2015) Vol. 125, Iss. 12, pp. 1857-1865
Open Access | Times Cited: 172
Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified
Sa A. Wang, Wayne Tam, Albert G. Tsai, et al.
Modern Pathology (2016) Vol. 29, Iss. 8, pp. 854-864
Open Access | Times Cited: 120
Gastric cancer: texture analysis from multidetector computed tomography as a potential preoperative prognostic biomarker
Francesco Giganti, Sofia Antunes, Annalaura Salerno, et al.
European Radiology (2016) Vol. 27, Iss. 5, pp. 1831-1839
Closed Access | Times Cited: 102
Acute Myeloid Leukemia: The Good, the Bad, and the Ugly
Andrew Kuykendall, Nicolas Duployez, Nicolas Boissel, et al.
American Society of Clinical Oncology Educational Book (2018), Iss. 38, pp. 555-573
Closed Access | Times Cited: 101
An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms
Tariq I. Mughal, Nicholas C.P. Cross, E. Padron, et al.
Haematologica (2015) Vol. 100, Iss. 9, pp. 1117-1130
Open Access | Times Cited: 98
Genomics of chronic neutrophilic leukemia
Julia E. Maxson, Jeffrey W. Tyner
Blood (2016) Vol. 129, Iss. 6, pp. 715-722
Open Access | Times Cited: 93
Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia
Kim-Hien T. Dao, Jason Gotlib, Michael M.N. Deininger, et al.
Journal of Clinical Oncology (2019) Vol. 38, Iss. 10, pp. 1006-1018
Open Access | Times Cited: 93
MDS overlap disorders and diagnostic boundaries
Tiffany Tanaka, Rafael Bejar
Blood (2019) Vol. 133, Iss. 10, pp. 1086-1095
Open Access | Times Cited: 80
Genomic landscape of neutrophilic leukemias of ambiguous diagnosis
Haijiao Zhang, Beth Wilmot, Daniel Bottomly, et al.
Blood (2019) Vol. 134, Iss. 11, pp. 867-879
Open Access | Times Cited: 76
Chronic Myeloid Leukemia, from Pathophysiology to Treatment-Free Remission: A Narrative Literature Review
Ikhwan Rinaldi, Kevin Winston
Journal of Blood Medicine (2023) Vol. Volume 14, pp. 261-277
Open Access | Times Cited: 31
CNL and aCML should be considered as a single entity based on molecular profiles and outcomes
Gonzalo Carreño‐Tarragona, Alberto Álvarez‐Larrán, Claire Harrison, et al.
Blood Advances (2023) Vol. 7, Iss. 9, pp. 1672-1681
Open Access | Times Cited: 25
Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management
Natasha Szuber, Attilio Orazi, Ayalew Tefferi
American Journal of Hematology (2024) Vol. 99, Iss. 7, pp. 1360-1387
Closed Access | Times Cited: 13
Turning the tide in myelodysplastic/myeloproliferative neoplasms
Michael W. Deininger, Jeffrey W. Tyner, Éric Solary
Nature reviews. Cancer (2017) Vol. 17, Iss. 7, pp. 425-440
Closed Access | Times Cited: 76
Genomics of Myeloproliferative Neoplasms
Katerina Zoi, Nicholas C.P. Cross
Journal of Clinical Oncology (2017) Vol. 35, Iss. 9, pp. 947-954
Open Access | Times Cited: 65
A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis
Lucia Masárová, Srđan Verstovšek, Juliana E. Hidalgo‐Lόpez, et al.
Blood (2018) Vol. 132, Iss. 16, pp. 1664-1674
Open Access | Times Cited: 64
Atypical chronic myeloid leukemia and myelodysplastic/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management
Mrinal M. Patnaik, Ayalew Tefferi
American Journal of Hematology (2023) Vol. 98, Iss. 4, pp. 681-689
Open Access | Times Cited: 21
The Contemporary Role of Hematopoietic Stem Cell Transplantation in the Management of Chronic Myeloid Leukemia: Is It the Same in All Settings?
Ibrahim Elmakaty, Giuseppe Saglio, Murtadha Al‐Khabori, et al.
Cancers (2024) Vol. 16, Iss. 4, pp. 754-754
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top